Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. (PubMed, Drug Des Devel Ther) - Jun 18, 2025 - "Letermovir is both effective and safe for CMV prophylaxis in pediatric patients following HCT, especially in patients with more risk factors of csCMVi. Grade II-IV GvHD increases the risk of csCMVi, while letermovir prophylaxis reduces the risk."
Journal • Aplastic Anemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pediatrics • Transplantation
|
|
Ai Zhang; Aiguo Liu; Jianxin Dun; Li Wang; Mengmeng Yin; Qun Hu; Wen Yu; Yao Wang; Yaqin Wang; Yongbing Zhu; Yu Xiang; Yuting Xu
|